Polymer Factory (POLYMER) Q4 2024 earnings summary

Executive summary

• Net sales in Q4 2024 rose 183% year-over-year to KSEK 538, with full-year sales up 6% to KSEK 1,690.

• Order received from a leading US-based biopharma company and a distribution agreement signed with AMR in Japan.

• Patent for DNG drug delivery platform granted in China and US; several MTAs signed for DNG.

• Participation in the EDF-funded NanoSHIELD project, with a 2.8 MSEK payment received in Q4.

Financial highlights

• Q4 net sales: KSEK 538 (190), up 183% year-over-year; full-year net sales: KSEK 1,690 (1,601), up 6%.

• Q4 loss: KSEK -620 (-1,311); full-year loss: KSEK -4,118 (-4,831).

• Q4 EPS: SEK -0.06 (-0.12); full-year EPS: SEK -0.38 (-0.45).

• Cash and bank at year-end: KSEK 1,715; equity: KSEK 3,463; equity/assets ratio: 58%.

• Cash flow from operations in Q4: KSEK 713 (-1,291); full-year: KSEK -2,924 (-2,484).

Outlook and guidance

• Ambition to build on increased Q4 revenues and achieve better balance between revenues and costs in 2025.

• Board assesses current liquidity, new share issue, and business plan sufficient to finance operations for the next 12 months.